INmune Bio, Inc.
NASDAQ:INMBBiotechnology
+$0.15 today
- Market cap
- $50.25M
- Beta
- 0.98
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.56
Volume 0.09M
Average 0.68M
INMB Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
INmune Bio, Inc.NASDAQ: INMB
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $52K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $108K.
Context
- Cost of revenue amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $52K or moves back toward the trailing-twelve-month quarterly average of $27K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How INMB compares with its peers on the latest reported figures
- INMB's LTM Mar 2026 cost of revenue of $108K is the 3rd highest of the 4 companies compared; the peer median is $203K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.85M | -69.5% | — | 20.6% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $203K | +1591.7% | — | — |
| LTM Mar 2026 | $108K | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding INMB) | $203K | -69.5% | — | 20.6% | |
Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 181K | 374K | 155K | 14K | 50K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 181K | 374K | 155K | 14K | 50K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 20.54M | 17.07M | 20.27M | 33.17M | 20.66M |
| Selling, General & Admin | 8.79M | 9.26M | 9.62M | 9.48M | 10.26M |
| Operating Expenses | 29.33M | 26.33M | 29.9M | 42.65M | 30.92M |
| Depreciation & Amortization | 29.15M | 25.95M | 29.74M | 553K | 84K |
| EBITDA | (1.19M) | (1.35M) | (267K) | (41.53M) | (45.85M) |
| EBITDA Margin | -655.8% | -360.4% | -172.3% | -296635.7% | -91698.0% |
| Operating Income | (29.15M) | (25.95M) | (29.74M) | (42.64M) | (30.87M) |
| Operating Margin | -16106.6% | -6938.8% | -19187.7% | -304535.7% | -61738.0% |
| Interest Income | 0 | 0 | 0 | 0 | 850K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.19M) | (1.35M) | (267K) | 553K | (15.06M) |
| Income Before Tax | (30.34M) | (27.3M) | (30.01M) | (42.08M) | (45.93M) |
| Pre-Tax Margin | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.34M) | (27.3M) | (30.01M) | (42.08M) | (45.93M) |
| Net Margin | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| EPS (Basic) | (1.88) | (1.52) | (1.67) | (2.11) | (1.86) |
| EPS (Diluted) | (1.88) | (1.52) | (1.67) | (2.11) | (1.86) |
| Weighted Avg Shares | 16.13M | 17.93M | 17.98M | 19.94M | 26.59M |
| Weighted Avg Shares (Diluted) | 16.13M | 17.93M | 17.98M | 19.94M | 26.59M |
INmune Bio, Inc.
NASDAQ:INMB
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.